Mavacamten
Obstructive Hypertrophic Cardiomyopathy (oHCM)
Approved (China NMPA Review)Asset for Sale/Partnership
Key Facts
Indication
Obstructive Hypertrophic Cardiomyopathy (oHCM)
Phase
Approved (China NMPA Review)
Status
Asset for Sale/Partnership
Company
About LianBio
LianBio's mission was to accelerate the availability of innovative medicines for patients in China and broader Asian markets by in-licensing clinical-stage assets from global partners. The company built an integrated regional development and commercialization platform to navigate complex regulatory and commercial landscapes. Its primary achievement was advancing a portfolio of promising candidates, including mavacamten for oHCM which reached NDA acceptance in China, before the Board's decision to wind down operations and liquidate the pipeline following a strategic review in November 2023.
View full company profileTherapeutic Areas
Other Obstructive Hypertrophic Cardiomyopathy (oHCM) Drugs
| Drug | Company | Phase |
|---|---|---|
| MYQORZO (aficamten) | Cytokinetics | Commercial |